The Latest Breaking News from Illumina

A wide range of applications across several sectors, supportive government initiatives, rapid technological advancements, and shifting market dynamics position the biotechnology industry for robust long-term growth. Given the industry’s bright outlook, biotech stocks MannKind (MNKD), Illumina (ILMN), and TG Therapeutics (TGTX) could be ideal watchlist additions for potential growth. Read…

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed down -0.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.17%. Stocks on Tuesday settled mixed. Reduced expectations for...

Illumina stock rose Monday after the company said it would divest its cancer detection outfit, Grail, following a lengthy court battle.

Illumina said Sunday it will the sell cancer detection startup after a U.S. appeals court said the $7.1 billion deal violated antitrust laws,

Illumina, a beacon in genetic science, is set to unfurl its stake in Grail-the stellar creator of cancer-detecting tests–in a dance of corporate divestiture.

Top health care investors Bob Kocher and Bryan Roberts share their annual predictions for the sector–and how last year's list panned out.

Illumina stock crashed Friday after the DNA-reading behemoth slashed its outlook as pressures continue to build on life sciences companies.

The European Union is ordering U.S. biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators

The Nasdaq and Nvidia fell below their 50-day moving averages, with AI stocks tumbling. Inflation data is on tap. Here's what to do now.